Kurs & Likviditet
Kalender
2025-02-18 | Bokslutskommuniké 2024 |
2024-11-07 | Kvartalsrapport 2024-Q3 |
2024-07-18 | Kvartalsrapport 2024-Q2 |
2024-05-08 | Ordinarie utdelning ENZY 0.00 SEK |
2024-05-07 | Årsstämma 2024 |
2024-04-25 | Kvartalsrapport 2024-Q1 |
2024-02-16 | Bokslutskommuniké 2023 |
2023-11-07 | Kvartalsrapport 2023-Q3 |
2023-07-18 | Kvartalsrapport 2023-Q2 |
2023-05-05 | Ordinarie utdelning ENZY 0.00 SEK |
2023-05-04 | Årsstämma 2023 |
2023-04-27 | Kvartalsrapport 2023-Q1 |
2023-02-17 | Bokslutskommuniké 2022 |
2022-11-02 | Kvartalsrapport 2022-Q3 |
2022-07-19 | Kvartalsrapport 2022-Q2 |
2022-04-29 | Ordinarie utdelning ENZY 0.00 SEK |
2022-04-28 | Kvartalsrapport 2022-Q1 |
2022-04-28 | Årsstämma 2022 |
2022-02-17 | Bokslutskommuniké 2021 |
2021-11-02 | Kvartalsrapport 2021-Q3 |
2021-10-18 | Extra Bolagsstämma 2021 |
2021-07-16 | Kvartalsrapport 2021-Q2 |
2021-05-06 | Ordinarie utdelning ENZY 0.00 SEK |
2021-05-05 | Årsstämma 2021 |
2021-04-29 | Kvartalsrapport 2021-Q1 |
2021-02-18 | Bokslutskommuniké 2020 |
2020-11-03 | Kvartalsrapport 2020-Q3 |
2020-07-16 | Kvartalsrapport 2020-Q2 |
2020-05-06 | Ordinarie utdelning ENZY 0.00 SEK |
2020-05-05 | Kvartalsrapport 2020-Q1 |
2020-05-05 | Årsstämma 2020 |
2020-02-13 | Bokslutskommuniké 2019 |
2019-11-05 | Kvartalsrapport 2019-Q3 |
2019-07-17 | Kvartalsrapport 2019-Q2 |
2019-05-08 | Ordinarie utdelning ENZY 0.00 SEK |
2019-05-07 | Årsstämma 2019 |
2019-05-07 | Kvartalsrapport 2019-Q1 |
2019-02-19 | Bokslutskommuniké 2018 |
2018-10-31 | Kvartalsrapport 2018-Q3 |
2018-07-17 | Kvartalsrapport 2018-Q2 |
2018-04-27 | Ordinarie utdelning ENZY 0.00 SEK |
2018-04-26 | Årsstämma 2018 |
2018-04-26 | Kvartalsrapport 2018-Q1 |
2018-02-14 | Bokslutskommuniké 2017 |
2017-11-01 | Kvartalsrapport 2017-Q3 |
2017-07-20 | Kvartalsrapport 2017-Q2 |
2017-04-21 | Ordinarie utdelning ENZY 0.00 SEK |
2017-04-20 | Kvartalsrapport 2017-Q1 |
2017-04-20 | Årsstämma 2017 |
2017-02-16 | Bokslutskommuniké 2016 |
2016-12-19 | Extra Bolagsstämma 2016 |
2016-11-03 | Kvartalsrapport 2016-Q3 |
2016-07-18 | Kvartalsrapport 2016-Q2 |
2016-05-25 | Årsstämma 2016 |
2016-04-22 | Ordinarie utdelning ENZY 0.00 SEK |
2016-04-18 | Kvartalsrapport 2016-Q1 |
2016-02-16 | Bokslutskommuniké 2015 |
2015-10-20 | Kvartalsrapport 2015-Q3 |
2015-07-21 | Kvartalsrapport 2015-Q2 |
2015-04-22 | Ordinarie utdelning ENZY 0.00 SEK |
2015-04-21 | Årsstämma 2015 |
2015-04-21 | Kvartalsrapport 2015-Q1 |
2015-02-17 | Bokslutskommuniké 2014 |
2014-12-19 | Extra Bolagsstämma 2014 |
2014-10-21 | Kvartalsrapport 2014-Q3 |
2014-07-22 | Kvartalsrapport 2014-Q2 |
2014-05-20 | Ordinarie utdelning ENZY 0.00 SEK |
2014-05-19 | Årsstämma 2014 |
2014-05-19 | Kvartalsrapport 2014-Q1 |
2014-02-04 | Bokslutskommuniké 2013 |
2013-11-13 | Kvartalsrapport 2013-Q3 |
2013-08-22 | Kvartalsrapport 2013-Q2 |
2013-05-21 | Kvartalsrapport 2013-Q1 |
2013-05-07 | Ordinarie utdelning ENZY 0.00 SEK |
2013-05-06 | Årsstämma 2013 |
2013-02-15 | Bokslutskommuniké 2012 |
2012-11-22 | Kvartalsrapport 2012-Q3 |
2012-08-23 | Kvartalsrapport 2012-Q2 |
2012-06-04 | 15-7 2012 |
2012-05-24 | Kvartalsrapport 2012-Q1 |
2012-05-16 | Kvartalsrapport 2012-Q1 |
2012-04-19 | Ordinarie utdelning ENZY 0.00 SEK |
2012-04-18 | Årsstämma 2012 |
2012-02-29 | Kvartalsrapport 2011-Q3 |
2012-02-29 | Bokslutskommuniké 2011 |
2011-12-22 | Kvartalsrapport 2011-Q2 |
2011-09-29 | Kvartalsrapport 2011-Q1 |
2011-09-16 | Ordinarie utdelning ENZY 0.00 SEK |
2011-09-15 | Årsstämma 2011 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Claus Egstrand assumes his role as CEO of Enzymatica three months ahead of schedule and takes office on September 9, 2021.
When Claus Egstrand was appointed new CEO in July, other engagements pointed at a possible start on January 1, 2022. As these other engagements have now come to an end, Claus Egstrand assumes his new role already on September 9, 2021. Therese Filmersson, acting CEO, returns to her previous role as CFO and has also been appointed Deputy CEO, as previously communicated. Bengt Baron returns to his previous role as Chairman of the Board.
For more information, please contact:
Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 (0)708 55 11 85 | Email: stefan.olsson@enzymatica.com
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases
Enzymatica's certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: certifiedadviser@penser.se